Eterna Therapeutics (Eterna Therapeutics) FCF Margin % : -27,417.65% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Eterna Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Eterna Therapeutics's Free Cash Flow for the three months ended in Dec. 2023 was $-4.66 Mil. Eterna Therapeutics's Revenue for the three months ended in Dec. 2023 was $0.02 Mil. Therefore, Eterna Therapeutics's FCF Margin % for the quarter that ended in Dec. 2023 was -27,417.65%.

As of today, Eterna Therapeutics's current FCF Yield % is -216.76%.

The historical rank and industry rank for Eterna Therapeutics's FCF Margin % or its related term are showing as below:

ERNA' s FCF Margin % Range Over the Past 10 Years
Min: -30039.71 Med: -30039.71 Max: -30011.76
Current: -30011.76

During the past 4 years, the highest FCF Margin % of Eterna Therapeutics was -30011.76%. The lowest was -30039.71%. And the median was -30039.71%.

ERNA's FCF Margin % is ranked worse than
95.34% of 1031 companies
in the Biotechnology industry
Industry Median: -148.24 vs ERNA: -30011.76

Eterna Therapeutics FCF Margin % Historical Data

The historical data trend for Eterna Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eterna Therapeutics FCF Margin % Chart

Eterna Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Margin %

-30,039.71

Eterna Therapeutics Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial											-	-	-	-11,423.53	-27,417.65

Competitive Comparison of Eterna Therapeutics's FCF Margin %

For the Biotechnology subindustry, Eterna Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Eterna Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eterna Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Eterna Therapeutics's FCF Margin % falls into.

Eterna Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Eterna Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-20.427	/	0.068
	=	-30,039.71 %

Eterna Therapeutics's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-4.661	/	0.017
	=	-27,417.65 %

Eterna Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Eterna Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Eterna Therapeutics (Eterna Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eterna Therapeutics Inc (NAS:ERNA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

1035 Cambridge Street, Suite 18A, Cambridge, MA, USA, 02141

Website

https://www.eternatx.com

Eterna Therapeutics Inc is a biopharmaceutical company. The company develops transformational new medicines using various cell engineering technology. It is engaged in developing breakthrough mRNA cell engineering technologies to repair cellular dysfunction and treat a range of therapeutic indications. With its strategic partners, the group is developing nucleic acid and cell therapies that can significantly improve the health outcomes of patients with high unmet medical needs.

Executives

Dorothy J Clarke	director	C/O ETERNA THERAPEUTICS INC., 1035 CAMBRIDGE STREET, STE. 18A, CAMBRIDGE MA 02141
Charles Cherington	10 percent owner	ONE BOW STREET, CAMBRIDGE MA 02138
Brant Binder	director	C/O TRUST CO OF THE SWEST, 200 PARK AVE SUITE 220, NEW YORK NY 01066
Richard W Wagner	director	C/O PRAECIS PHARMACEUTICALS INC, 830 WINTER ST, WALTHAM MA 02451
Curtis W Huft	10 percent owner	4510 LAMESA HWY, SNYDER TX 79549
Freebird Partners Lp	10 percent owner	2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
Freebird Investments Llc	10 percent owner	2800 POST OAK BLVD., SUITE 2000, HOUSTON TX 77056
John D Halpern	10 percent owner
Nicholas Jason Singer	director	1395 BRICKELL AVENUE, SUITE 800, MIAMI FL 33131
William A. Wexler	director	12 GILL STREET, SUITE 4650, WOBURN MA 01801
Gregory Fiore	director	10355 SCIENCE CENTER DRIVE, SUITE 150, SAN DIEGO CA 92121
Andrew C. Jackson	officer: Chief Financial Officer	11988 EL CAMINO REAL STE. 650, SAN DIEGO CA 92130
Matthew Angel	officer: Interim President and CEO	10531 4S COMMONS DRIVE, SUITE 160-550, SAN DIEGO CA 92127
Heather B Redman	director	TWO NORTH NINTH STREET, ALLENTOWN PA 18101
Erin S. Enright	director	666 PLAINSBORO ROAD, PLAINSBORO NJ 08536